These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 25764674)
1. [JSH guidelines for the management of hepatitis C virus infection (version 3)]. Tanaka A Nihon Rinsho; 2015 Feb; 73(2):221-7. PubMed ID: 25764674 [TBL] [Abstract][Full Text] [Related]
2. [Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2014 in Japan]. Suzuki F Nihon Rinsho; 2015 Feb; 73(2):215-20. PubMed ID: 25764673 [TBL] [Abstract][Full Text] [Related]
3. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Kudo M; Izumi N; Kokudo N; Matsui O; Sakamoto M; Nakashima O; Kojiro M; Makuuchi M; Dig Dis; 2011; 29(3):339-64. PubMed ID: 21829027 [TBL] [Abstract][Full Text] [Related]
4. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. Mack CL; Gonzalez-Peralta RP; Gupta N; Leung D; Narkewicz MR; Roberts EA; Rosenthal P; Schwarz KB; J Pediatr Gastroenterol Nutr; 2012 Jun; 54(6):838-55. PubMed ID: 22487950 [TBL] [Abstract][Full Text] [Related]
5. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology Hepatol Res; 2020 Jul; 50(7):791-816. PubMed ID: 32343477 [TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Nagao Y; Kimura K; Kawahigashi Y; Sata M Clin Transl Gastroenterol; 2016 Jul; 7(7):e179. PubMed ID: 27388424 [TBL] [Abstract][Full Text] [Related]
7. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132 [TBL] [Abstract][Full Text] [Related]
9. JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis. Asahina Y; Hepatol Res; 2020 Jul; 50(7):775-790. PubMed ID: 32298527 [TBL] [Abstract][Full Text] [Related]
10. Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel. Ranieri R; Starnini G; Carbonara S; Pontali E; Leo G; Romano A; Panese S; Monarca R; Prestileo T; Barbarini G; Babudieri S; Infection; 2017 Apr; 45(2):131-138. PubMed ID: 28025726 [TBL] [Abstract][Full Text] [Related]
11. Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid. de Ruiter PE; Gadjradj Y; de Knegt RJ; Metselaar HJ; Ijzermans JN; van der Laan LJ World J Transplant; 2018 Sep; 8(5):156-166. PubMed ID: 30211024 [TBL] [Abstract][Full Text] [Related]
12. Current clinical care compared with new Dutch guidelines for hepatitis C treatment. Slavenburg S; Lamers MH; Roomer R; de Knegt RJ; van Oijen MG; Drenth JP Neth J Med; 2009 May; 67(5):177-81. PubMed ID: 19581667 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition. Indolfi G; Fischler B; Gonzalez-Peralta RP; Ciocca M; Porta G; Neelam M; El-Guindi M; Kelly D; Ni YH; Sibal A; Leung DH; Chang MH; J Pediatr Gastroenterol Nutr; 2020 May; 70(5):711-717. PubMed ID: 32205770 [TBL] [Abstract][Full Text] [Related]
14. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819 [TBL] [Abstract][Full Text] [Related]
15. Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir. Baba H; Tajiri K; Nagata K; Kawai K; Minemura M; Sugiyama T Case Rep Gastroenterol; 2016; 10(2):352-9. PubMed ID: 27504082 [TBL] [Abstract][Full Text] [Related]
16. Current race in the development of DAAs (direct-acting antivirals) against HCV. De Clercq E Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613 [TBL] [Abstract][Full Text] [Related]
17. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient. Rodríguez-Torres M Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341 [TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus: standard-of-care treatment. Pawlotsky JM Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Sheridan DA; Neely RD; Bassendine MF Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):10-6. PubMed ID: 22959093 [TBL] [Abstract][Full Text] [Related]